Safety toxicology studies of SK609 in rats have shown the maximum tolerated dose of SK609 is 30mg/kg and all the doses used in this study are well within the no-observed-adverse-effect level of SK609[1].
SK609 shows the maximum tolerated dose of SK609 is 30mg/kg in safety toxicology study within the no-observed-adverse-effect level of SK609[2].
In the cynomolgus macaques PK study, oral administration of SK609 (0.5, 2 and 4 mg/kg) is associated with mean Cmax values of 13.7, 69.3 and 218 ng/ml respectively, occurring at (Tmax) 4.1, 6.4 and 5.0 hours following administration and with corresponding AUC(0-t) values of 171, 904 and 2938 h.ng/ml respectively[3].Following intravenous administration (2 mg/kg), SK609 had a mean terminal half-life of 7.9 h in plasma.SK609 (i.p.; 2, 4, 6, 8, 10, 20 mg/kg) significantly improves the performance of the impaired paw and also normalized the bilateral asymmetry associated with the hemiparkinson rat[3].
